Financial Contrast: Progenics Pharmaceuticals (PGNX) and Insys Therapeutics (INSY)

Progenics Pharmaceuticals (NASDAQ: PGNX) and Insys Therapeutics (NASDAQ:INSY) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Progenics Pharmaceuticals and Insys Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Progenics Pharmaceuticals 0 0 3 1 3.25
Insys Therapeutics 0 2 2 0 2.50

Progenics Pharmaceuticals presently has a consensus price target of $13.75, indicating a potential upside of 153.69%. Insys Therapeutics has a consensus price target of $9.67, indicating a potential upside of 26.36%. Given Progenics Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Progenics Pharmaceuticals is more favorable than Insys Therapeutics.

Risk and Volatility

Progenics Pharmaceuticals has a beta of 3.4, suggesting that its stock price is 240% more volatile than the S&P 500. Comparatively, Insys Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

Insider and Institutional Ownership

84.7% of Progenics Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.3% of Insys Therapeutics shares are owned by institutional investors. 3.6% of Progenics Pharmaceuticals shares are owned by insiders. Comparatively, 67.9% of Insys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Progenics Pharmaceuticals and Insys Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Progenics Pharmaceuticals $69.43 million 5.49 $10.80 million ($0.79) -6.86
Insys Therapeutics $242.27 million 2.32 $7.59 million ($2.55) -3.00

Progenics Pharmaceuticals has higher earnings, but lower revenue than Insys Therapeutics. Progenics Pharmaceuticals is trading at a lower price-to-earnings ratio than Insys Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Progenics Pharmaceuticals and Insys Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Progenics Pharmaceuticals -445.81% -67.61% -31.51%
Insys Therapeutics -112.56% -11.76% -7.90%


Progenics Pharmaceuticals beats Insys Therapeutics on 9 of the 15 factors compared between the two stocks.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply